Clinical Trial Update: Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of autologous tumor infiltrating lymphocytes with high-dose interleukin-2 in select solid tumors was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Tumor infiltrating lymphocytes (TIL) (tumor infiltrating lymphocytes)

Snippet

Sponsor: Gregory Daniels | Conditions: Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2025-07-03